Masimo Corp.‘s nearly $33.8 million settlement earned a federal court’s final approval, resolving investor allegations that the medical technology company and top executives overhyped financial projections following a 2022 acquisition.
Magistrate Judge Daniel E. Butcher approved a settlement class Wednesday of those who got Masimo stock from May 4, 2022, to Aug. 8, 2023. The settlement ends all claims against Masimo, its billionaire founder Joe Kiani, and three other current and former executives. Kiani, who resigned as Masimo’s CEO in 2024 after an activist investor challenge ended in shareholders ousting him from the company’s board, wasn’t one of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.